Dermatological conditions are one of the most common types of disorders worldwide, from which approximately more than half of the population suffers. For the past decades, the majority of the dermatology market has remained saturated with established products for example acne has reached it saturation with respect to its biologics and new product pipeline. Since R&D is a never ending process and has led to new product pipeline. The clinical and commercial success of biologics in the treatment of dermatological conditions, as well as advancements in the understanding of the disease pathways of many dermatological conditions, has led to a renewed interest of pharmaceutical companies in the dermatology market, and subsequently the emergence of an innovative pipeline. The prevalence of various skin disease varies according to geographical area, race, environment and other socioeconomic factors. Disease like eczema and dermatitis were known to be high among the developed countries whereas developing countries like Africa and Asia have highest predominant skin disease.
Nestle and Allergan had been the most active assignees in the year 2016. The patents/published applications majorly focus on novel compounds followed by vitamins as a part of dermatological composition. Nestle and GlaxoSmithKline were the most active assignees in the year 2017.The top priority country observed is China with a filing of 2752 patents followed by the US with 1179 patents/published applications, which indicates most innovations are originating in China. Interestingly, countries like Italy, Russia, Spain and Sweden are also active in the domain. Growth in dermatological market in the US in primarily driven due to variety of factors as such rising incidence of skin disease, rapid increase in healthcare expenditure and increasing awareness about aesthetic procedures. Growth in the dermatology market is witnessed at an increasing and accelerating pace in an upcoming and recent years.
This report covers most prevalent dermatological disorders, with a particular focus on major key diseases as: psoriasis, atopic dermatitis, acne vulgaris as these conditions have the highest prevalence and also has the largest pipeline. The global dermatology is expected to grow in billions in upcoming years. Key drivers of this growth will be the uptake of recently approved premium biologics, as well as promising late-stage products that are expected to be highly valuable, growing awareness among people with respect to aging and emphasis to look good and presentable and also increasing incidence of skin disease. Therefore, in nutshell the global dermatology market is expected to grow substantially due to promising novel product pipeline. The market size for dermatology therapeutics is expected to grow considerably, from $19.8 billion in 2016 to $41.2 billion in 2026, at a CAGR of 8 percent. Hence understanding the growth in patient epidemiology and market revenues for the dermatology market globally, among the key various players with respect to their product types is a major focus of the dermatology market outlook.
The key players dominating the dermatology market profiled in this report includes Novan, Vyome, Foamix, BioPharmX, Paratek, Sun Pharmaceuticals, Mankind, Cipla, Glenmark, Amgen, AbbVie, Valeant. Opportunity for the development of new products and services are high, as the market consists of recognized players and their big brands.
Key questions answered
- Prevalence of Common Dermatological Disease; 2013
- Global Dermatology Market; 2016-2026
- Global Dermatology Market by Disease Type; 2016-2026
- Global Dermatology Market by M&A Deals; 2011-2016
- US Dermatology Market; 2016-2026
- EU Dermatology Market; 2016-2026
- Japan Dermatology Market; 2016-2026
- India Dermatology Market; 2016-2026
- Global Dermatology OTC Products Market; 2016-2026
- US Dermatology OTC Products Market; 2016-2026
- EU5 Dermatology OTC Products Market; 2016-2026
- Japan Dermatology OTC Products Market; 2016-2026
- India Dermatology OTC Products Market; 2016-2026
- Publication Year Trend in Dermatology Market; 2013-2018
- Earliest Priority Country Filing Trend in Dermatology Market; 2013-2018
- Dermatology Trends by Disease Type; 2013-2018
- Dermatology Patent Trend by Focus Area
- Dermatology Patent Trend by Compositions; 2013-2018
- Dermatology Patent Trend by Route of Administration; 2013-2018
- Dermatology Market Trend by Key Players;2013-2018
- Top Inventors in Dermatology Market; 2012-2017
- Percentage of Aging Population over 65 years; 1950-2050
- Research Institutions Associated with Dermatology; 2015
- Number of Dermatologist in the US; 2010-2014
- Number of Dermatologists in the US; 1970-2040
- Growth in Melanoma Diagnosis; 2000-2009
- Novan R&D Expenditure; 2014-2017
- Foamix Pharmaceuticals Revenue
- Foamix R&D Expenses; 2013-2017
- BioPharmX Corporation Revenue; 2017-2018
- BioPharmX Corporation R&D Expenses; 2013-2017
- Paratek Revenue, 2013-2017
- Paratek R&D Expenses (2013-2017)
- Sun Pharmaceuticals Revenue; 2013-2017
- Sun Pharmaceuticals R&D Expenditure; 2013-2017
- Mankind Revenue; 2012-2016
- Cipla Limited Revenue; 2013-2017
- Cipla Limited R&D Expenses; 2013-2017
- Glenmark Pharmaceuticals Revenue; 2013-2017
- Amgen Revenue; 2012-2016
- AbbVie Revenue; 2013-2017
- AbbVie R&D Expenses; 2013-2017
- Valeant Pharmaceuticals Revenue; 2012-2016
- Valeant R&D Expenses; 2013-2017
Executive Summary
1. Introduction
I. Fields of Dermatology
II. Dermatological Diseases
III. Treatment
2. Epidemology
3. Dermatology Therapeutics Market Outlook & Forecast
I. Global Dermatology Market
a. Global Dermatology Market by Disease Type
b. Global Dermatology Market by Fields
c. Global Dermatology Market by M&A
d. Global Dermatology Market Share by Regions
II. US Dermatology Market
III. Europe Dermatology Market
IV. Japanese Dermatology Market
V. Indian Dermatology Market
4.Dermatology OTC Market Outlook Forecast
I. Global Dermatology OTC Products Market
II. US Dermatology OTC Products Market
III. Europe Dermatology OTC Products Market
IV. Japanese Dermatology OTC Products
V. Indian Dermatology OTC Products Market
VI. Rise of herbal or organic products
VII. Rise in demand of multi-functional products
5. Patent Landscape
I. Overall IP Trends
II. Dermatology Patent Trends by Disease Type
III. Dermatology Patent Trends by Focus Area
a. Dermatology Patent Trends by Composition
b. Dermatology Patent Trends by Route of Administration
III. Key Patents in Dermatology Market
IV. Dermatology Market Patent Trend by Key Players
V. Dermatology Market Patent Trend by Key Inventors
6. Growth Drivers
I. Increasing Consumer Awareness
II. Rising Incidence of Skin Diseases
III. Aging Population
IV. Growth in Institutions Associated with Dermatology
7. Challenges
I. Delay in Diagnosis
II. Unclear Distinction Between Normal Skin Disease and Cosmetic Skin Problems
III. Rising Demand Outpacing the Number of Available Dermatologistss
8. Trends
I. Change in Retinol Formulation
II. Advent of New Products & Techniques
III. Increase in Skin Cancer Diagnosis
9. Company Profiling
I. Novan Inc.
a. Business overview
b. Financial overview
c. Business strategy
II. Vyome Biosciences Pvt. Ltd.
a. Business overview
b. Financial overview
c. Business strategy
III. Foamix Pharmaceuticals Ltd.
a. Business overview
b. Financial overview
c. Business strategy
IV. BioPharmX Corporation
a. Business overview
b. Financial overview
c. Business strategy
V. Paratek Pharmaceuticals, Inc.
a. Business overview
b. Financial overview
c. Business strategy
VI. Sun Pharmaceuticals Ltd.
a. Business overview
b. Financial overview
c. Business strategy
VII. Mankind Pharmaceuticals
a. Business overview
b. Financial overview
c. Business strategy
VIII. Cipla Ltd.
a. Business overview
b. Financial overview
c. Business strategy
IX. Glenmark Pharmaceuticals Limited
a. Business overview
b. Financial overview
c. Business strategy
X. Amgen
a. Business overview
b. Financial overview
c. Business strategy
XI. Abbvie
a. Business overview
b. Financial overview
c. Business strategy
Fig 1.1 Fields of Dermatology
Fig 1.2 Type of Dermatological DiseasesFig 1.2 Type of Dermatological Diseases
Fig 1.3 Types of Dermatological Therapies and Treatments
Fig 2.1 Dermatological Disease by Age Group; 2011
Fig 2.2 Prevalence of Common Dermatological Disease; 2013
Fig 3.1 Global Dermatology Market; 2016-2026
Fig 3.2 Global Dermatology Market by Disease Type; 2016-2026
Fig 3.3 Global Dermatology Market Share by Fields; 2015
Fig 3.4 Global Dermatology Market by M&A Deals; 2011-2016
Fig 3.5 Global Dermatology Market Share by Regions; 2016
Fig 3.6 US Dermatology Market; 2016-2026
Fig 3.7 EU5 Dermatology Market; 2016-2026Fig 2.13: US cosmetics market by value; 2012-2026
Fig 3.8 Japan Dermatology Market; 2016-2026
Fig 3.9 Indian Dermatology Market; 2016-2026
Fig 4.1 Global Dermatology OTC Products Market; 2016-2026
Fig 4.2 US Dermatology OTC Products Market; 2016-2026
Fig 4.3 EU5 Dermatology OTC Products Market; 2016-2026
Fig 4.4 Japan Dermatology OTC Products Market; 2016-2026
Fig 4.5 India Dermatology OTC Products Market; 2016-2026
Fig 5.1 Publication Year Trend in Dermatology Market; 2013-2018
Fig 5.2 Earliest Priority Country Filing Trend in Dermatology Market; 2013-2018
Fig 5.3 Dermatology Trends by Disease Type; 2013-2018
Fig 5.4 Dermatology Patent Trend by Focus Area
Fig 5.5: Dermatology Patent Trend by Compositions; 2013-2018
Fig 5.6 Dermatology Patent Trend by Route of Administration; 2013-2018
Fig 5.7 Dermatology Market Trend by Key Players;2013-2018
Fig 5.8 Top Inventors in Dermatology Market; 2012-2017
Fig 6.1 Percentage of Aging Population over 65 years; 1950-2050
Fig 6.2 Research Institutions Associated with Dermatology; 2015
Fig 6.3 Number of Dermatologist in the US; 2010-2014
Fig 7.1 Number of Dermatologists in the US; 1970-2040
Fig 8.1 Growth in Melanoma Diagnosis; 2000-2009
Fig 9.1 Novan R&D Expenditure; 2014-2017
Fig 9.2 Novan Inc Pipeline Drugs
Fig9.3 Vyome Biosciences Pipeline Drugs
Fig 9.4 Vyome Biosciences MRTTM platform Product Portfolio
Fig 9.5 Foamix Pharmaceuticals Revenue
Fig 9.6 Foamix R&D Expenses; 2013-2017
Fig 9.7 Foamix Pharmaceuticals Product Pipeline
Fig 9.8 Foamix Patented Class of Foam Formulations
Fig 9.9 BioPharmX Corporation Revenue; 2017-2018
Fig 9.10 BioPharmX Corporation R&D Expenses; 2013-2017
Fig 9.11 BioPharmX Corporation Pipeline Drugs
Fig 9.12 Paratek Revenue, 2013-2017
Fig 9.13 Paratek R&D Expenses (2013-2017)
Fig 9.14 Paratek Pharmaceuticals Pipeline Drugs
Fig 9.15 Sun Pharmaceuticals Revenue; 2013-2017
Fig 9.16 Sun Pharmaceuticals R&D Expenditure; 2013-2017
Fig 9.17 Product Pipeline
Fig 9.18 Mankind Revenue; 2012-2016
Fig 9.19 Mankind Revenue by segmentation; 2012-2016
Fig 9.20 Cipla Revenue; 2013-2017
Fig 9.21 Cipla Limited R&D Expenses; 2013-2017
Fig 9.22 Glenmark Pharmaceuticals Revenue; 2013-2017
Fig 9.23 Glenmark Pharmaceuticals Revenue by Regions; 2013-2017
Fig 9.24 Amgen Revenue; 2012-2016
Fig 9.25 Amgen Product Sales; 2016
Fig 9.26 AbbVie Revenue; 2013-2017
Fig 9.27 AbbVie R&D Expenses; 2013-2017
Fig 9.28 AbbVie Product Sales; 2016
Fig 9.29 AbbVie Product Pipeline
Fig 9.30 Valeant Pharmaceuticals Revenue; 2012-2016
Fig 9.31 Valeant Pharmaceuticals Revenue by Segments; 2012-2016
Fig 9.32 Valeant R&D Expenses; 2013-2017
Fig 9.33 Valeant Product Pipeline